Table 2.
Study settings of the 12 reviewed ESMO 2022 trial presentations
| Study name | Tumor type | Treatment setting | Assigned treatment Comparator arm |
Assigned treatment Intervention arm |
Blinded allocation |
|---|---|---|---|---|---|
| TROPICS02 | HR-positive HER2-negative breast cancer | Advanced, ≥3rd line | Treatment of physicians’ choice | Sacituzumab govitecan | No |
| MonarcHER | HR-positive Her2-positive breast cancer | Advanced, ≥3rd line | Trastuzumab + investigators’ choice chemotherapy | Abemaciclib/trastuzumab ± fulvestrant | No |
| CodeBreak200 | krasG12C-mutated NSCLC | Advanced, 2nd line | Docetaxel | Sotorasib | No |
| IPSOS | NSCLC, no EGFR or ALK sensitizing mutation | Advanced, 1st line, not fit for platinum-doublet therapy | Investigators’ choice chemotherapy | Atezolizumab | No |
| COSMIC313 | Intermediate- or poor-risk clear-cell RCC | Advanced, 1st line | Ipilimumab/nivolumab + placebo | Ipilimumab/nivolumab + cabozantinib | Yes |
| CheckMate 914 | RCC | Adjuvant | Placebo | Ipilimumab/nivolumab | Yes |
| HR-IRI-APC | Pancreatic cancer | Advanced, 2nd line | 5FU/LV | 5FU/LV + liposomal irinotecan | No |
| NICHE2 | Mismatch repair-deficient colon cancer | Neoadjuvant | No comparator arm | Ipilimumab/nivolumab | No |
| 309/KEYNOTE-775 | Endometrial cancer | Advanced, 2nd line | Treatment of physicians’ choice | Lenvatinib/pembrolizumab | No |
| SOLO1/GOG-3004 | BRCA-mutated ovarian cancer | FIGO stage III/IV, responding to platinum-based therapy | Placebo | Olaparib maintenance | Yes |
| DeFi | Desmoid tumor | Advanced, ≥2nd line | Placebo | Nirogacestat | Yes |
| TILs in melanoma | Melanoma | Advanced, 1st or 2nd line | Ipilimumab | TILs | No |
FIGO, International Federation of Gynecology and Obstetrics; FU, fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LV, leucovorin; NSCLC, non-small-cell lung cancer; RCC, renal cell cancer; TILs, tumor-infiltrating lymphocytes.